At BilizBio, we are committed to revolutionizing the future of healthcare through cutting-edge biotechnological innovations. Our focus is on developing transformative therapies that address unmet medical needs in areas of high global impact. With a robust pipeline of novel biologics and a relentless pursuit of scientific excellence, BilizBio is at the forefront of discovering and delivering next-generation solutions for complex diseases.

1st

First-mover advantage in treating neurological diseases intranasally

$5.3B

Market opportunity for initial treatment indication in Parkinson's Disease

+$4.0B

Market opportunity targeting additional formulations + drug-device combinations

Intranasal Platform Solution for Neurological Diseases

Proprietary airflow system delivers high-velocity, rifled drug dispersion for precise nasal targeting

Enables direct and rapid drug transport to the brain within minutes via neural and vascular pathways

Temperature-stable spray-dried powders enhance absorption through the nasal lining for greater brain exposure and optimizing neurological efficacy and ensure drug is active even in extreme environments

Investor Resources

>> View the Blitz BioPharma Investor Presentation

Investment Considerations

Transformational Technology:

First-to-Market Intranasal Delivery Platform That Bypasses the Blood-Brain Barrier, Enabling Rapid and Targeted Treatment for Neurological Disorders.

Targeting High-Growth Market Potential:

Positioned to capture significant market share in the $5.3 billion Parkinson’s treatment market, with near-future applications for many other neurological disorders.

Compelling Value Proposition:

Non-invasive, temperature-stable spray-dry formulations reduce toxicity, improve compliance and revive previously failed high-toxicity drugs.

Near-Term Exit Opportunity:

The abbreviated development process leverages candidates that are either FDA-approved or have demonstrated safety and proof of concept in Phase II trials, enabling a streamlined path to market and early exit potential.